Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes

被引：0
|
作者：
Rouette, Julie [1 ,2 ]
Douros, Antonios [1 ,2 ,3 ,4 ,5 ,6 ]
Yin, Hui [1 ]
Yu, Oriana Hoi Yun [1 ,7 ]
Filion, Kristian B. [1 ,2 ,8 ]
Azoulay, Laurent [1 ,2 ,9 ]
机构：
[1] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
[2] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[3] Charite Univ Med Berlin, Inst Clin Pharmacol & Toxicol, Berlin, Germany
[4] Free Univ Berlin, Berlin, Germany
[5] Humboldt Univ, Berlin, Germany
[6] Berlin Inst Hlth, Berlin, Germany
[7] Jewish Gen Hosp, Div Endocrinol, Montreal, PQ, Canada
[8] McGill Univ, Dept Med, Montreal, PQ, Canada
[9] McGill Univ, Gerald Bronfman Dept Oncol, Montreal, PQ, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
10018
引用
收藏
页码：AB47 / AB47
页数：1
相关论文
共 50 条
  • [1] Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
    Douros, Antonios
    Rouette, Julie
    Yin, Hui
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    [J]. DIABETES CARE, 2019, 42 (08) : 1496 - 1503
  • [2] Dipeptidyl Peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes: A population-based cohort study
    Douros, Antonios
    Rouette, Julie
    Yin, Hui
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 225 - 226
  • [3] Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors
    Gravani, A.
    Gaitanis, G.
    Tsironi, T.
    Tigas, S.
    Bassukas, I. D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (12) : E438 - E439
  • [4] Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study
    Wu, Chen-Yi
    Wu, Chun-Ying
    Li, Chung-Pin
    Chou, Yiing-Jenq
    Lin, Yi-Hsian
    Chang, Yun-Ting
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 171
  • [5] Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'
    Fania, L.
    Di Zenzo, G.
    Mazzanti, C.
    Abeni, D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (12) : E439 - E440
  • [6] Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology
    Murakami, Takaaki
    Yabe, Daisuke
    Inagaki, Nobuya
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (05) : 1168 - 1170
  • [7] Genetic susceptibility of dipeptidyl Peptidase-4 inhibitor associated bullous pemphigoid in Chinese patients with type 2 diabetes
    Shi, Mai
    Yang, Aimin
    Chow, Elaine
    Lau, Eric S. H.
    Tam, Claudia H. T.
    Kong, Alice P. S.
    Luk, Andrea O. Y.
    Ma, Ronald C. W.
    Cheung, Christina M. T.
    Chan, Juliana C. N.
    Chan, Agnes W. S.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (03) : E375 - E377
  • [8] Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history
    Fernando Garcia-Gil, Miguel
    Lezcano Biosca, Victoria
    Garcia Garcia, Mar
    Monte Serrano, Juan
    Aldea Manrique, Beatriz
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2021, 97 (1143) : 51 - 52
  • [9] Dipeptidyl peptidase-4 inhibitors and the risk of biliary tract diseases among patients with type 2 diabetes
    Shapiro, Samantha B.
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 83 - 84
  • [10] A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
    Aouidad, Iman
    Fite, Charlotte
    Marinho, Eduardo
    Deschamps, Lydia
    Crickx, Beatrice
    Descamps, Vincent
    [J]. JAMA DERMATOLOGY, 2013, 149 (02) : 243 - 245
12345